Thwarting dyskinesia by targeting mTORC1

Research output: Contribution to journalShort surveypeer-review


In a mouse model of Parkinson's disease, new evidence shows that L-DOPA, which is used to treat the symptoms of the disease but also causes dyskinesia, results in a persistent activation of the protein kinase mTOR (mammalian target of rapamycin) in a subset of striatal medium spiny neurons. Moreover, blockade of a specific type of mTOR signaling (mTORC1) prevents the development of dyskinesia, but not the antiakinetic benefits produced by L-DOPA. Thus, mTORC1 may be a viable therapeutic target for dyskinesia caused by L-DOPA treatment in patients with Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)pe42
JournalScience signaling
Issue number80
StatePublished - Jul 21 2009

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Thwarting dyskinesia by targeting mTORC1'. Together they form a unique fingerprint.

Cite this